Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARDIMMUN

Financiado

Cerrado

A new therapeutic antibody with a personalised medicine approach in cardiovascul...

A new therapeutic antibody with a personalised medicine approach in cardiovascular disease The project, CARDIMMUN, aims to pursue development of the scientific findings from the FP6 project CVDImmune. Based on our patented discovery, that low levels of anti-PC (phosphorylcholine) indicate risk for future development of... ver más

31/07/2016

Leiden University...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-07-31 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

Leiden University Medical Ce...

0.00€ | Lider

SMERUD

N.D. | Participante

UNIVERSITY OF TURKU

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ABCardionostics Human Antibody-enabled Cardiovascular Personalized Theranosi... 4M€ Cerrado

VAMPIRE Vascular antibody mediated pharmaceutically induced tumour r... 1M€ Cerrado

chemos Chemical Hematology breaking resistance of hematological ma... 147K€ Cerrado

PCIN-2017-093 ANTICUERPOS ANTI-FARMACOS Y DETECCION MOLECULAR DE FARMACOS... 121K€ Cerrado

TopSpec Next generation precision antibody profiling from science... 4M€ Cerrado

PRe-ART-2T Predictive REagent-Antibody Replacement Technology stage 2-T... 800K€ Cerrado

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The project, CARDIMMUN, aims to pursue development of the scientific findings from the FP6 project CVDImmune. Based on our patented discovery, that low levels of anti-PC (phosphorylcholine) indicate risk for future development of cardiovascular disease, we have developed both a diagnostic test (a marker to identify cardiovascular disease patients that are at high risk of secondary events) and a candidate drug - an innovative fully human monoclonal antibody antibody, PC-mAb - that can block vascular inflammation. Together, this forms a unique opportunity for a personalised medicine approach, with a companion diagnostic and a targeted intervention in an area that is still in great medical need, despite recent advances in therapy. PC-mAb is now ready for clinical development. The project will be progressed, by a structured plan that brings together SMEs and selected academic partners, and integrates preclinical and clinical studies into a commercially viable and mature therapeutic modality. The 5 work packages will embrace concept testing in animal models using biomarkers applicable also in human disease, coronary flow reserve and glucose uptake in inflamed arteries, as well as required toxicity studies. Additionally, studies in man are planned that explores safety, pharmacokinetics, pharmacodynamics and indices of clinical efficacy, including a placebo-controlled Proof of Activity trial in patients. Athera’s PC-mAb is targeting the market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. According to plan, the data will enable a business agreement with Athera and a partner (probably big pharma) to enter into larger scale clinical trials by early 2017. PC-mAb could then be launched on the market as a new drug, with clear block-buster potential, by year 2020.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores